#avastin ovarian cancer

[indiangenm]

Bevacizumab 400 mg is primarily used in the treatment of several cancers such as metastatic colorectal cancer, cervical cancer, glioblastoma, non-squamous non-small cell lung cancer, and ovarian cancer. As a promising humanized monoclonal antibody, Bevacizumab 400 mg works by targeting VEGF-A, a protein that promotes blood vessel growth around tumors, thereby inhibiting cancer progression. Indian Generic Medicines (IGM) provides Bevacizumab 400 mg for patients in countries where it may be unavailable or unapproved. For more information on accessing this therapeutic drug, reach out via Call/WhatsApp: +91 8130290915.

[omkarpatel]

Ovarian Cancer Drugs: Fighting a Silent Killer

Ovarian cancer is often referred to as the "silent killer" due to its difficulty in detection at an early stage. While ovarian cancer accounts for only about 3% of all cancers in women, it causes more deaths than any other cancer of the female reproductive system. Fortunately, major advances have been made in ovarian cancer drugs that are helping more women survive this disease. This article provides an overview of some key drugs used to treat ovarian cancer. Platinum-Based Chemotherapy Drugs Platinum-based chemotherapy drugs, such as carboplatin and cisplatin, have been the standard treatments for ovarian cancer for decades. These drugs work by cross-linking DNA strands in cancer cells, preventing them from replicating. Though extremely toxic, platinum drugs are effective at destroying fast-growing cancer cells. In the first-line treatment of ovarian cancer, carboplatin is usually administered along with paclitaxel or another chemotherapy drug to increase effectiveness. While platinum drugs are not curative on their own, they significantly improve survival rates when used as part of initial treatment. angiogenesis inhibitors disrupt the formation of new blood vessels that tumors need to grow. One such drug used to treat ovarian cancer is bevacizumab (Avastin). As an angiogenesis inhibitor, bevacizumab starves tumors of nutrients and oxygen by blocking vascular endothelial growth factor (VEGF). Studies have found bevacizumab improves progression-free survival when combined with chemotherapy as a first-line or maintenance treatment for ovarian cancer. The drug is also being examined as a potential treatment for recurrent disease. Side effects can include high blood pressure, bleeding, problems wound healing and gastrointestinal perforations. Careful monitoring is required with bevacizumab treatment. PARP Inhibitors: A New Target Poly (ADP-ribose) polymerase, or PARP, inhibitors are an exciting new class of drugs for ovarian cancer. PARP is an enzyme involved in DNA repair. PARP inhibitors work by blocking cancer cells already deficient in homologous recombination repair, like those with BRCA gene mutations, from repairing DNA damage. This leaves the cancer vulnerable to cell death. In 2017, the FDA approved the PARP inhibitor olaparib (Lynparza) for the maintenance treatment of recurrent ovarian cancer patients with a BRCA mutation who have responded to platinum-based chemotherapy. More recently, it was approved for germline BRCA-mutated advanced ovarian cancer after three or more lines of chemotherapy. Rubraca (rucaparib) and Zejula (niraparib) are two other PARP inhibitors approved to treat ovarian cancer. Ongoing research continues to explore the potential of PARP inhibitors in different treatment settings and biomarker populations. Side effects can include fatigue, nausea, vomiting, diarrhea and low blood cell counts.

[sanjeevseo]

Function of Avastin Injection

The generic medication Bevacizumab is sold under the brand name Avastin Injection. It is a drug that is used to treat several different types of cancer, including colorectal, lung, and ovarian cancer. The medication Avastin Injection is a member of is categorised as an anti-angiogenesis agent. They function by preventing the development of fresh blood vessels, which tumours require for growth and dissemination.

Avastin injection exporters from Mumbai play an essential role Avastin injection exporters in India have built a trustworthy supply chain. Avastin injection exporters make sure the drug is delivered on schedule to various locations throughout the world. Avastin injection can slow or even diminish tumour growth by preventing the development of new blood vessels. In some circumstances, it can aid in symptom improvement and prolong life.

How Does Avastin Injection Work?

Avastin Injection functions by inhibiting the establishment of new blood vessels. They provide tumours with the nutrition and oxygen they require to grow and spread. This protein, known as vascular endothelial growth factor (VEGF), is what causes the development of new blood vessels.

For tumours to survive and continue to develop over a certain size, a blood supply is necessary. VEGF is a vital factor in this process. Avastin Injection stops the activity of VEGF, which can limit the tumour's access to nutrients and oxygen. They prevent the development of new blood vessels in and around the tumour.

Additionally, by enhancing their capacity to reach and destroy cancer cells, chemotherapy and radiation therapy may also be more successful. This is when combined with Avastin Injection. Avastin Injection is used to slow down or even reduce tumours. It may help to alleviate symptoms and, in some situations, extend lives.

Which Medical Conditions Are Manageable With Avastin Injection?

Several forms of malignancies, including the following, are treated with avastin injection:

Carcinoma Of The Colon

As a first-line therapy for metastatic colorectal cancer, avastin injection is combined with chemotherapy.

Lung Cancer

Advanced non-small cell lung cancer is treated with avastin injection in conjunction with chemotherapy.

Breast Cancer

Chemotherapy is combined with avastin injection in the treatment of HER2-negative metastatic breast cancer.

Uterine Cancer

For the treatment of platinum-resistant recurrent ovarian cancer, Avastin Injection is used with chemotherapy.

Tumours Of The Renal Cells

For the treatment of advanced renal cell carcinoma, avastin injection is used in conjunction with interferon alfa.

Glioblastoma

Glioblastoma in adults with recurring tumours is treated with avastin injection.

Cancer Of The Cervix

For the treatment of metastatic, chronic, or recurrent cervical cancer, avastin injection is used in conjunction with chemotherapy.

Avastin Injection is administered intravenously, which means that it is injected right into a vein. A healthcare practitioner typically administers it in a hospital or medical setting. Improved patient treatment outcomes are the goal of Avastin Injections future improvements. It would therefore be more available and less expensive.

Conclusion

Avastin Injection is the subject of current research and development. This is being done to examine its potential for treating various cancer types and to increase its efficacy and security. The use of Avastin Injection in conjunction with other medications is being researched. Avastin Injection is being studied and produced in biosimilar forms. This may enhance patient access to this critical treatment and offer more cheap options.

[mcatmemoranda]

One of my pts has colon CA that metastasized to her liver. She was so nice and that makes me sad. Her oncologist recommended FOLFOX and bevacizumab q2 weeks.

FOLFOX is a chemotherapy regimen for treatment of colorectal cancer: folinic acid, fluorouracil, and oxaliplatin.

Bevacizumab (Avastin) can treat colorectal, lung, glioblastoma, kidney, cervical, and ovarian cancer

[delvenservices]

Oncology Market Size, Share, Demand, Growth, Trends & Forecast: 2028

Oncology Market By Areas (Medical, Surgical, Radiation), Cancer Type (Haematology Cancer, Ovarian Cancer, Pancreatic Cancer, Lung Cancer, Bladder Cancer, Prostate Cancer, Breast Cancer, Kidney Cancer, Others), Treatment (Combination Therapy, Adjuvant Therapy, Supportive Therapy, Palliative Care, Others), Technology (Car-T Cell Therapy, CRISPR/CAS9, Others), Drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Imbruvica, Velcade, Zytiga, Xtandi, Others), Stage (Stage I, Stage II, Stage III, Stage IV), End Users (Hospitals, Specialty Clinics, Oncology Centers, Surgical Centers, Others), Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America)

Global oncology market is anticipated to reach USD 175.4 billion by 2020 growing at a CAGR of 7.1% during the forecasting period, 2020-2028.

Oncology is one of the branches of medicine which deals prevention, diagnosis, and treatment of cancer. It includes the medical, surgical and radiation oncology. Medical oncology is of various types like chemotherapy, targeted therapy and immunotherapy. Factors such as increasing demand for minimally invasive procedures and the increasing number of targeted populations are some of the major drivers for the oncology market.

Request Sample Pages of Report: https://www.delvens.com/get-free-sample/oncology-market-trends-forecast-till-2028

Key Findings

Global oncology market is segmented into areas, cancer type, treatment, technology, drugs, stage, end-user and geography.

Areas segment is segmented into Medical, Surgical and Radiation. Medical segment is further segmented into chemotherapy, Targeted Therapy and Immunotherapy. Surgical segment is further segmented into Image-Guided Biopsy, Fine Needle Aspiration Biopsy, Core Needle Biopsy, Vacuum-Assisted Biopsy, Excisional Biopsy, Shave Biopsy, Punch Biopsy, Endoscopic Biopsy, Laparoscopic Biopsy, Bone Marrow Aspiration and Biopsy, Liquid Biopsy.

Cancer Type segment is segmented into Haematology Cancer, Ovarian Cancer, Pancreatic Cancer, Lung Cancer, Bladder Cancer, Prostate Cancer, Breast Cancer, Kidney Cancer and Others

Treatment segment is segmented into Combination Therapy, Adjuvant Therapy, Supportive Therapy, Palliative Care and Others

Technology segment is segmented into Car-T Cell Therapy, CRISPR/CAS9 and Others

Drugs segment is segmented into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Imbruvica, Velcade, Zytiga, Xtandi and Others

Stage segment is segmented into Stage I, Stage II, Stage III and Stage IV

End Users segment is segmented into Hospitals, Specialty Clinics, Oncology Centers, Surgical Centers and Others.

Geographically, global oncology market is sub segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America and insights are provided for each region and major countries within the regions.

To Grow Your Business Revenue, Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/oncology-market-trends-forecast-till-2028

Regional Analysis

North America region is the largest contributor to the oncology market in the forecast period 2020-2028 and Asia-Pacific region is expected to grow with the highest CAGR during the forecast period 2020-2028.

Competitive Landscape

Key players in global oncology market are

Roche,

BMS Pharmaceuticals,

Novartis,

Johnson & Johnson,

Takeda Pharmaceuticals,

Pfizer Inc.,

Eli Lilly,

Merck & Co.,

Amgen,

Abbvie,

Allogene Therapeutics,

Juno Therapeutics,

Morphosys,

Arcus Biosciences,

Atreca,

Autolus,

Novocure

Recent Developments

The companies have come up with various promotional activities in from of launch, investment, acquisition and other, for instance:

Boston Scientific announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc. a company headquartered in the United Kingdom, which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as acute care pharmaceuticals 

Medtronic Plc announced its U.S. launch of OptiSphere (TM) embolization spheres, a resorbable embolic platform designed for embolization of hypervascular tumors

Hence, tremendous progress have been made over the last decade and yet a lot more to come in the recent years.

Direct Order for the Report: https://www.delvens.com/checkout/oncology-market-trends-forecast-till-2028

Reasons to Acquire

Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors

Gain authentic and granular data access for oncology market so as to understand the trends and the factors involved behind changing market situations

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

SALES@DELVENS.COM

[markettrendus]

Global Avastin (Ovarian Cancer) Market Analysis, Company Profiles, Industry Development Strategies To 2029

Global Avastin (Ovarian Cancer) Market Analysis, Company Profiles, Industry Development Strategies To 2029

Global Avastin (Ovarian Cancer) Market Growth 2022-2029 by Market.biz presents a comprehensive picture of this market from a worldwide viewpoint. End-users can benefit from this complete market research report with all the required useful information about this market. The Global Avastin (Ovarian Cancer) report covers a descriptive analysis with detailed segmentation, complete research and…

[enal-agzakhana]

Avastin Injection Uses, Dosage, Side Effects, Precautions

Avastin Injection Uses, Dosage, Side Effects, Precautions

Important to know about Avastin Injection ?

Bevacizumab is a monoclonal antibody. This is a targeted anti-cancer agent ( ‘targeted therapy’). It reduces proliferation of blood vessels.

Avastin Injection Uses, Dosage, Side Effects, Precautions

Physicians write it for at cancerof the colon, the rectum (the last part of the rectum), the breasts, lungs, kidney, cervix, ovaries, and fallopian tubes…

[reveal-the-news]

EC Grants Celltrion Avastin Biosimilar Marketing Authorization

EC Grants Celltrion Avastin Biosimilar Marketing Authorization

The European Commission has approved Celltrion Healthcare’s bevacizumab biosimilar for marketing across the European Union, making it the seventh bevacizumab biosimilar approved in the region. Vegzelma (CT-P16) was approved for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian…

[vinaykmalviyamd]

Immunotherapy In Gynecologic Cancer

Cancer is the excessive growth of cells, and gynecologic cancer affects the female reproductive organs. It usually begins in a woman’s pelvis between the stomach and hip bones. Common symptoms of gynecologic cancer are pressure or pain in the pelvic region and vulva itching, irritation, and burning.

However, gynecologic cancer is also characterized by changes in vulva skin color, leading to sores, rashes, warts, and ulcers. According to Vinay K. Malviya M.D, a qualified and experienced health professional, gynecologic cancer can increase urination episodes, and cause constipation, bloating, and diarrhea.

Sometimes, it also causes abnormal vaginal discharge and bleeding. The patient may also experience severe pain in the abdomen and spine. Vulvar, vaginal uterine, ovarian, and cervical are common types of gynecologic cancer. In addition, fallopian tube cancer is another type of gynecologic cancer, but this rarely occurs.

Although cancer has different treatments available, immunotherapy has gained popularity in recent years, thanks to fewer side effects and complications. It uses a person’s immune system to combat cancer cells.

Vinay K. Malviya M.D says that health professionals perform immunotherapy in various ways, such as stimulating or boosting a person’s natural defense mechanisms to attack cancer cells. Read on!

Table of Contents

Immunotherapy In Gynecologic Cancer

Immunotherapies for Ovarian Cancer

Immunotherapies for Cervical Cancer

Final Words

Immunotherapy In Gynecologic Cancer

Immunotherapy is an evidence-based, advanced, cutting-edge treatment for cancer treatment. It strengthens your body’s immune system to identify, target, control, fight, and kill cancer cells. Immunotherapy drugs, vaccines, and other medications can help your immune system:

Attack cancer cells without affecting the healthier ones

Constantly adapt to changes in the cancer cells

Reassess the condition of the cells to modify the attack strategy

Kill cancer cells even if it recurs without harming the healthy ones

Strengthen the immune system to boost cancer-killing capabilities

See also  How Does Alcohol Affect the Whole Body?

Health professionals use immunotherapy treatment with other therapies, such as chemotherapy, surgery, radiation, or targeted therapies, leading to increased effectiveness and reliability. Let us discuss a few categories of immunotherapy for gynecologic cancer.

Cancer Vaccines

Vinay K. Malviya M.D says cancer vaccines have two categories: cancer treatment and cancer prevention. Today, the medical sector has made available various cancer prevention vaccines.

Likewise, treatment vaccines are also available, but most are under research and investigation. Scientists make efforts to determine whether treatment vaccines can identify and kill specific cancers, such as gynecologic cancer.

T-Cell Therapy

T-Cell Therapy is another type of immunotherapy used for treating cancer cells. The procedure involves extracting the patient’s T-cells from the blood and adding a laboratory-made receptor to these cells. A health professional inserts the T-cells with a receptor back into the patient’s body. These receptors identify, recognize, and kill cancer cells.

Monoclonal Antibodies

According to Vinay K. Malviya M.D, monoclonal antibodies are another type of immunotherapy category that involves the development of antibodies in the laboratory. These antibodies slow the growth of cancer cells by preventing the abnormal proteins from developing fast.

Immunotherapies for Ovarian Cancer

Avastin, also known as Bevacizumab, is a targeted antibody drug used for ovarian cancer treatment. An anti-angiogenic monoclonal antibody targets the VEGF and VEGFR pathway and prevents blood vessels from developing a tumor.

The primary function of this immunotherapy drug is to stop the blood flow to the cancer cells, preventing them from growing faster. Most health professionals combine this treatment with chemotherapy for more effectiveness.

See also  Things you should know about chocolate

Immunotherapies for Cervical Cancer

According to Vinay K. Malviya M.D, Tivdak, also known as Tisotumab Vedotin, is an immunotherapy drug used for cervical cancer treatment. It is an antibody-based medication that targets tissue factors to stop cervical tumors’ growth.

Besides, Keytruda or Pembrolizumab is another monoclonal antibody that plays a critical role in blocking the PD-1 proteins on cancer cells developed in a woman’s cervical region.

The purpose is to prevent cancer cells from behaving as normal or healthy cells. Likewise, the antibody allows the T-cells to quickly speed up their process and attack/kill cancer cells.

Final Words

Immunotherapy is promising cancer prevention or treatment methodology. Several immunotherapy drugs and vaccines are available for gynecologic cancers, such as ovarian, cervical, and vaginal cancer.

Common side effects of immunotherapy for gynecologic cancer patients are flu, cough, rash, diarrhea, nausea, fatigue, headaches, body aches, and inflammation. However, these side effects are manageable and do not lead to complications.

Resource : https://www.scoopearth.com/vinay-k-malviya-m-d-immunotherapy-in-gynecologic-cancer/ 

[radioclasic]

O ieșeancă bolnavă de cancer și-a câștigat în justiție tratamentul

O ieșeancă bolnavă de cancer și-a câștigat în justiție tratamentul

Instanţa a fost singura soluţie pentru ca o ieșeancă diagnosticată cu cancer cerebral să obțină dreptul la tratament compensat, anunță Ziarul de Iași. Avastin, medicamentul prescris de medici unei ieșence nu a putut fi achiziționat pentru că acesta figura compensat 100% doar pentru pentru cancer colorectal, bronhopulmonar, renal și ovarian, nu și pentru cancer cerebral de care suferea Alina P. Un…

[marketresearchtrendsblog]

Monoclonal Antibodies Market: Revenue Growth, Key Players, Qualitative Analysis, Forecast 2020-2028

The monoclonal antibody market is estimated to represent a global market of USD 135.6 billion by 2025 with growth rate of 4.8%. Biologics industry has been constantly on rise which strongly support the growth of monoclonal antibody market. Due to this fact, the utilization of monoclonal antibody has increased over the past few years owing to the increased awareness of these therapeutics among physicians and patients.For example, in 2012, approximately 20% of the total pharmaceutical revenue generated from biologic products and is anticipated to increase around 25% by the end of 2018. Furthermore, successful commercialization of monoclonal antibodies like Avastin, Rituxan and Remicade further boosted the customer base. For example, mAbs such as Avastin clocked more than US$ 6 billion of sale across the globe in 2013. Increasing uptake of these therapeutics support the market development. The market covers the analysis of the commercial or pipeline monoclonal antibody therapeutics such as Humira (adalimumab, anti-TNF), Enbrel, Remicade, Rituxan, Avastin, Herceptin, Lucentis, Erbitux, Eylea and many others.The global market is categorized in terms of source, end use and diseases. Based on source, the market is divided in murine, chimeric, humanized and human. Humanized and human segments are accounted for the largest share of the global market. Reason behind the high growth of this segments as these are considered as a natural drug and offers good safety on in vivo use.Synagis, Herceptin, Zenapax, Myelotarg, Campath, Xolair, Raptiva, Avastin, Tsyabri, Humira, Vectibix , and Cosentyx are some of the examples of human or humanized monoclonal antibodies. In terms of diseases, the market is segmented as autoimmune diseases, Inflammatory diseases, Infectious diseases and others. The utilization of monoclonal antibody therapeutics in cancer treatments and autoimmune diseases is whooping the market growth. Continuous rise in the incidence rate of cancer and autoimmune diseases along with growing demand for effective therapeutics in these area drive the market growth to great extent. End user segment is divided as hospitals, research laboratories and others. Hospitals segment dominated the market, captured almost 41.23% share of the global market in 2016.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-53378 Regionally, developed regions such as North America and Europe are considered to be the largest market. Of which, North America accounted for almost 50% share of the global market in 2016. Increasing number of research and development activities coupled with rise in awareness among end users about monoclonal antibody drives the market growth. U.S. based Pfizer, Inc. is currently researching on avelumab—monoclonal antibody for indications such as non-small cell lung cancer, ovarian cancer, and others. These companies spenda significant share of their revenue on research activities, to develop novel mAbs. Europe is also considered to capture significant market share, 25% global share in 2016. Increasing approval of novel monoclonal antibodies is expected to stimulate the market demand. In 2012, European Medicines Agency (EMA) released guidelines on biosimilar mAb development. This guideline demonstrates the capability of biosimilar mAbs with an interest in development of similar biological mAbs, leading to drive market growth. Asia Pacific and Latin American countries are projected to grow with the promising growth rate during the future period. Companies such as F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc, Novartis AG; Pfizer; Shanghai Junshi Bioscience Co., Ltd, Daiichi Sankyo Company, Ltd., and others are operating in this market. These companies are engaged in strategic merger and acquisitions to expand their market share in this market. For example, Roche, Inc. acquired California based Genentech which has helped company to expand its market share in monoclonal antibody segment. Aside from Roche, Abbott Laboratories also exhibit strong potential in the monoclonal antibody sector. Growth of this company is attributed to its acquisition of Knoll Pharmaceutical Co. unit and licensing rights to MedImmune’s Synagis and Numax. Further, Johnson & Johnson enhance its market presence supported by the strong growth of Stelara (ustekinumab), Simponi (golimumab), and bapineuzumab. The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2015 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2016 to 2025 for every reported segment. The years considered for the study are: Historical Year – 2014 & 2015 Base Year – 2015 Estimated Year – 2016 Projected Year – 2025 TARGET AUDIENCE Traders, Distributors, And Suppliers Hospitals Manufacturers Government and Regional Agencies and Research Organizations Consultants Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows: MARKET, BY SOURCE Murine Chimeric Humanized Human MARKET, BY DISEASE Autoimmune diseases Inflammatory diseases Infectious diseases others MARKET, BY END USE Hospitals Research labs Others MARKET, BY REGION North America Europe Asia Pacific Rest of the World MARKET, BY COUNTRY Further Breakdown of The North America Market U.S. Canada Further Breakdown of The Europe Market Germany France Rest of Europe Further Breakdown of The APAC Market India China Rest of APAC Further Breakdown of The Rest of the World Market Middle-East and Africa Latin America

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

[tumblingxelian]

Petitions

Hon Greg Hunt MP  Minister for Health  Parliament House  CANBERRA ACT 2600: Help support women or men with Metastatic Breast Cancer by signing our petition - Sign the Petition! https://chn.ge/2KvoZvc via @ChangeAUS

Disability Support for Fibromyalgia Sufferers of Australia - Sign the Petition! https://chn.ge/2Kvp1Dk via @ChangeAUS

Australia’s Newborns should be counted as patients and keeping them together with mothers should not come at a price. - Sign the Petition! https://chn.ge/2KF358b via @ChangeAUS

Turnbull government: Please Don't Impose Considerable Financial Hardship on Older Australians in the Very Late of Their Lives - Sign the Petition! https://chn.ge/2KzLOy5 via @ChangeAUS

Greg Hunt MP: Greg Hunt, MP: Please review the criteria for use of Avastin in Ovarian Cancer on the PBS - Sign the Petition! https://chn.ge/2KNKjv8 via @ChangeAUS

Coronial Inquest into William Tyrrell's disappearance - Sign the Petition! https://chn.ge/2KtYMND via @ChangeAUS

Have laws changed for child abusers and punishment - Sign the Petition! https://chn.ge/2KtbDzH via @ChangeAUS

John Quigley: Do Not Release Dante Arthurs - Sign the Petition! https://chn.ge/2KJUDV3 via @ChangeAUS

Australia: Resignation of David Morrison as Australian of the Year. - Sign the Petition! https://chn.ge/2KvoVLY via @ChangeAUS

[kunalcmi]

INDIA IMMUNE-ONCOLOGY DRUGS MARKET ANALYSIS  - (2018-2026)

Immuno-Oncology refers to the use of body’s natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

Increasing prevalence of cancer in India is expected to drive India Immune-Oncology Drugs Market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

However, factors such as high-cost associated with immuno-oncology therapies makes it unaffordable for population in the low and middle-income class, to opt for these therapies, thus restraining growth of the market. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg. Moreover, according to the World Health Organization (WHO), in February 2018, around 70% of deaths from cancer occur in low and middle-income countries. This can be attributed to high-prices of oncology therapies, which cannot be afforded by patients with low incomes.

Request Sample Free Copy of Report here: https://www.coherentmarketinsights.com/insight/request-sample/2631

Download PDF Brochure:https://www.coherentmarketinsights.com/insight/request-pdf/2631

Key features of the study:

This report provides in-depth analysis of the India Immune-Oncology Drugs Market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the India immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited and Hetero Drugs Limited.

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

India immuno-oncology drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for India immuno-oncology drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

India Immuno-Oncology Drugs Market, By Drug Type:

Immune Checkpoint Inhibitors

Nivolumab (Opdivo)

Atezolimumab (Tecentriq)

Pembrolizumab (Keytruda)

Durvalumab (Imfinzi)

Monoclonal Antibodies

Rituximab (Rituxan)

Trastazumab (Herceptin)

Bevacizumab (Avastin)

Nimotuzumab (Biomab EGFR)

Pertuzumab (Perjeta)

Ado-Trastuzumab Emtansine (Kadcyla)

Cancer Vaccines

Gardasil

Cervarix

India Immuno-Oncology Drugs Market, By Cancer Type:

Lung Cancer

Blood Cancer

Breast Cancer

Ovarian Cancer

Cervical Cancer

Colorectal Cancer

Stomach Cancer

Head & Neck Cancer

Others

Company Profiles

Amgen, Inc.*

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

Hoffmann-La Roche AG

Intas Pharmaceuticals Ltd.

AstraZeneca plc

Mylan N.V.

Reddy's Laboratories

Bristol - Myers Squibb

Merck & Co., Inc.

BIOCAD-Biotechnology company

Reliance Life Sciences

Biocon Limited

Hetero Drugs Limited

“*” marked represents similar segmentation in other categories in the respective section.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Explore CMI Services here

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Source: https://www.coherentmarketinsights.com/market-insight/india-immune-oncology-drugs-market-2631

[mucinousovariancancercoalition]

Treating Women with Mucinous Ovarian Cancers

Ovarian cancers are broadly grouped as epithelial, sex cord stromal, or germ cell tumors. Epithelial ovarian cancers, which account for 90% of all ovarian cancers, are made up of serous, endometrioid, mucinous, clear cell, and transitional cell carcinomas.

In the past, all epithelial ovarian cancers were treated alike. Doctors lumped all these different subtypes together and recommended similar surgical and chemotherapy approaches. More recently, we have begun to realize that the tumors under the “epithelial” umbrella behave uniquely and each respond differently to standard chemotherapy drugs. For that reason, we have started to treat these tumors more individually with different chemotherapy regimens for each of them.

Primary mucinous ovarian cancers account for a small fraction (3%–5%) of all epithelial ovarian cancers. These tumors can often grow quite large before detection. Because they look similar under the microscope, it is difficult to differentiate primary mucinous ovarian cancer from gastrointestinal cancers that have spread to the ovaries. A general rule of thumb is that if the tumor involves only one ovary and is >10 cm in size, it is likely a primary mucinous ovarian cancer.

If the tumor is on both ovaries, however, and <10 cm in size, it is more likely a metastatic tumor from a gastrointestinal primary. As the site of origin (ovary or gastrointestinal) can often be ambiguous, we recommend both an upper endoscopy and a colonoscopy for all patients with mucinous malignancies on the ovary to rule out a gastrointestinal primary before calling it ovarian cancer.

As primary mucinous ovarian cancer can grow quite large while frequently remaining on just one ovary, 85% of primary mucinous ovarian cancers will be diagnosed as stage I (e.g., limited to the ovary only). Patients with stage I disease have a very good prognosis and most will be cured of their cancer. Unfortunately, 15% of patients will have disease spread beyond the ovary at time of diagnosis (stages III or IV). In these patients, a long-term cure is difficult because the standard chemotherapy historically used for epithelial ovarian cancers (carboplatinum and paclitaxel) do not work as well in patients with mucinous ovarian cancer as compared to women with the more common serous ovarian cancer.

For that reason, many medical professionals advocate for a different treatment approach for women with stage III/IV primary mucinous ovarian cancer. Because these tumors look and behave like mucinous cancers of the gastrointestinal system, we believe the optimal chemotherapy regimen should be similar to those drugs given for treating gastrointestinal cancers as opposed to typical ovarian cancers. Therefore, instead of prescribing carboplatinum and paclitaxel for our patients with mucinous ovarian cancer, we have been using the GI regimen of oxaliplatin and 5-FU (or capecitabine). When approved by insurance companies, we also add a third drug called bevacizumab (avastin).

Colleagues and I have recently published a paper showing that this GI regimen may improve survival in women with mucinous ovarian cancer. To be clear, there is uncertainty as to what is the best treatment for this disease. If your doctor has given, or wants to give, carboplatinum and paclitaxel, that is certainly within the standard of care and one of the options approved by the National Comprehensive Cancer Network (NCCN). We just don’t believe it works as well as other options and have changed our practice to adopt this other approach.

For recurrent or progressive disease, there are limited options and we strongly recommend exploring clinical trials. For patients with recurrent disease, we will typically order molecular testing. These tests look for specific mutations within individual cancer cells. There are now many targeted drug therapies which are designed to attack these specific mutations. Sometimes this is called “personalized medicine” as drugs are chosen based on individual tumor mutations as opposed to combining all patients with a similar tumor together. For example, almost 50% of mucinous ovarian cancers will harbor a mutation in the KRAS gene. There are multiple drugs both approved by the FDA and used in clinical trials that are designed to exploit the KRAS mutation and increase cancer killing effects.

For those interested in molecular testing, this can be done at some large cancer centers or can be ordered through commercial companies, such as Foundation Medicine or Caris.

About the Author

This article was contributed by Michael M. Frumovitz, MD, MPH, FACOG. A leading voice in mucinous ovarian cancer, Dr. Frumovitz is a professor in the Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, at the University of Texas MD Anderson Cancer Center.

Read more about Dr. Frumovitz and other physicians who are working to improve the survival rates and quality of life for women with this rare disease.

[adwaitcoherent]

By 2026, India Immune-Oncology Drugs Market To Surpass US$ 461.8 Million - Coherent Market Insights

India Immune-Oncology Drugs Market To exhibit a CAGR of 13.1% over the forecast period (2018 - 2026)

Request for Sample PDF Copy:

https://www.coherentmarketinsights.com/insight/request-pdf/2631

Description:

Immuno-Oncology refers to the use of body’s natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

 Market Dynamics

 Increasing prevalence of cancer in India is expected to drive India Immuno-Oncology Drugs market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

 However, factors such as high-cost associated with immuno-oncology therapies makes it unaffordable for population in the low and middle-income class, to opt for these therapies, thus restraining growth of the market. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg. Moreover, according to the World Health Organization (WHO), in February 2018, around 70% of deaths from cancer occur in low and middle-income countries. This can be attributed to high-prices of oncology therapies, which cannot be afforded by patients with low incomes.

 Key features of the study:

 This report provides in-depth analysis of the India immuno-oncology drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the India immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited and Hetero Drugs Limited.

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

India immuno-oncology drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for India immuno-oncology drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

 India Immuno-Oncology Drugs Market, By Drug Type:

Immune Checkpoint Inhibitors

Nivolumab (Opdivo)

Atezolimumab (Tecentriq)

Pembrolizumab (Keytruda)

Durvalumab (Imfinzi)

Monoclonal Antibodies

Rituximab (Rituxan)

Trastazumab (Herceptin)

Bevacizumab (Avastin)

Nimotuzumab (Biomab EGFR)

Pertuzumab (Perjeta)

Ado-Trastuzumab Emtansine (Kadcyla)

Cancer Vaccines

Gardasil

Cervarix

India Immuno-Oncology Drugs Market, By Cancer Type:

Lung Cancer

Blood Cancer

Breast Cancer

Ovarian Cancer

Cervical Cancer

Colorectal Cancer

Stomach Cancer

Head & Neck Cancer

Others

Company Profiles

Amgen, Inc.*

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

Hoffmann-La Roche AG

Intas Pharmaceuticals Ltd.

AstraZeneca plc

Mylan N.V.

Reddy's Laboratories

Bristol - Myers Squibb

Merck & Co., Inc.

BIOCAD-Biotechnology company

Reliance Life Sciences

Biocon Limited

Hetero Drugs Limited

“*” marked represents similar segmentation in other categories in the respective section.

About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.

 Buy Report Here:

https://www.coherentmarketinsights.com/insight/buy-now/2631

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave.  #3200  Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[pharmanewstrands-blog]

Ovarian Cancer Drugs Market Pipeline Analysis 2018

Ovarian cancer is one of the most dreadful type of cancer widely found in women. In this cancer, abnormal cells growth is experienced in the ovaries, which has potential to invade or adversely affect other body parts such as abdomen layers, lining of the bowel and bladder, lymph nodes, and liver. Initial stages of ovarian cancer are associated with few vague symptoms, which further manifest as the cancer grows. These symptoms include inflating, pelvic ache, abdominal puffiness, and loss of appetite.

Request A Sample Copy: http://bit.ly/2mk94EF

Ovarian cancer is a relatively rare cancer as compared to other types, though risk is higher among women who have ovulated more over their lifetime, which can also include females who have never borne a child and those who began ovulating at a very young age. According to American Cancer Society, around 10% of ovarian cancer cases are related to inherited genetic risk. Women with mutations in BRCA1 or BRCA2 genes have 50% chance of developing breast or ovarian cancer. Ovarian carcinoma, is the most common ovarian cancer that accounts for 95% of cases, globally.

Ovarian cancer drugs market supported by growing aging population in the U.S. and U.K.

Rising number of ovarian cancer cases recorded over the recent past, is creating a highly conducive environment for growth of the ovarian cancer drugs market. According to American Cancer Society, in 2016, around 22,280 new cases of ovarian cancer were diagnosed, leading to 14,240 deaths in the U.S. According to the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute data, an increase in all new cancer cases is recorded, with ovarian cancer accounting for 1.3% of the incidence rate, and 2.4% of all related deaths, in 2016. The number of new ovarian cancer cases account for 11.9 per 100,000 women, and the total deaths account for 7.5 per 100,000 women, annually.

According to World Cancer Research Fund International data on the basis of highest rate of ovarian cancer by country: Fiji, age standardized rate per 100,000 is 14.9, followed by Latvia and Bulgaria with age standardized rate per 100,000 being 14.2 and 14.0, respectively. The U.K. stands tenth, with age standardized rate per 100,000 pegged at 11.7. Around 58% of ovarian cancer cases are diagnosed in emerging economies, with the highest incidence rate recorded in Africa and Asia Pacific. In the U.K., around 46% of women diagnosed with ovarian cancer, survive for around five years or more following the onset of the disease. According to Australian Government, Cancer Australia, as of 2017, 1,580 new ovarian cancer cases are estimated to be diagnosed, accounting for 2.5% of ovarian cancer cases among all new cancer cases in the country. This is estimated to result in 1,047 deaths in 2017. Thus, the ovarian cancer drugs industry is expected to gain significant traction in developed regions, in the near future.

Current scenario in ovarian cancer drugs market: High prevalence of ovarian cancer among women over 60 years in the U.S. and U.K.

Regional segmentation of the global ovarian cancer drugs market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest market share, mainly due to presence of major players and adoption of advanced medical technologies in countries such as the U.S. and Canada.

According to American Cancer Society, most of the ovarian cancer cases are reported among women aged 60 years and above. According to Cancer Research UK, in 2014, 7,378 new cases of ovarian cancer were reported in the country, of which around 53% of cases diagnosed were among females aged 65 years and above.

Combinational drug approach, a novel approach in the ovarian cancer drugs market

Key players operating in the ovarian cancer drugs market include Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, and F. Hoffman-La Roche Ltd. Major companies in this market are constantly working towards introducing innovative products and lowering production costs in order to enhance profitability. For instance, Roche’s blockbuster drug Avastin (bevacizumab) used in combination with carboplatin and paclitaxel is being used to treat ovarian cancer.

Key Developments

Research and development related to the diagnosis and treatment of ovarian cancer is expected to offer lucrative opportunities for market players. For instance, in August 2019, researchers from The George Washington University School of Medicine and Health Sciences, U.S. identified ovarian cancer drug resistance protein that needs to be blocked for the treatment of patients with platinum-resistant ovarian cancer.

Click To Read More On: Ovarian Cancer Drugs Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com